0.2012  -0.004 (-1.85%)		10-13 16:00
Open: 0.2012 High: 0.2012 Volume: 5,945,141		Pre. Close: 0.205 Low: 0.2012 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	0.25	1-year :	0.28
Resists	First :	0.22	Second :	0.24
Pivot price	0.2
Supports	First :	0.18	Second :	0.14
MAs	MA(5) :	0.2	MA(20) :	0.2
	MA(100) :	1.24	MA(250) :	1.73
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	40	D(3) :	40.8
RSI	RSI(14): 15.7
52-week	High :	6.44	Low :	0.18

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EPIX ] has closed above bottom band by 44.8%. Bollinger Bands are 95% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.2 - 0.2	0.2 - 0.2
Low:	0.2 - 0.2	0.2 - 0.2
Close:	0.2 - 0.2	0.2 - 0.2

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Thu, 09 Oct 2025
Alexis Bio, Inc completed the acquisition of ESSA Pharma Inc. for $80.4 million. - MarketScreener

Thu, 09 Oct 2025
ESSA Announces Completion of Arrangement with XenoTherapeutics - Stock Titan

Thu, 09 Oct 2025
ESSA Announces Completion of Arrangement with XenoTherapeutics - The Globe and Mail

Mon, 06 Oct 2025
99.83% Vote: ESSA Securityholders Approve Acquisition by XenoTherapeutics; Completion Expected Oct 9 - Stock Titan

Tue, 30 Sep 2025
ESSA Pharma (EPIX) Moves Forward with XenoTherapeutics Acquisiti - GuruFocus

Wed, 24 Sep 2025
$0.26 Total Value Per Share: ESSA Pharma Updates XenoTherapeutics Merger Agreement with New CVR Terms - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	47 (M)
Shares Float	33 (M)
Held by Insiders	5.6 (%)
Held by Institutions	73.6 (%)
Shares Short	1,220 (K)
Shares Short P.Month	3,660 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.45
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-15.3 %
Return on Equity (ttm)	-21.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-21 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-0.36
PEG Ratio	0
Price to Book value	0.08
Price to Sales	0
Price to Cash Flow	-0.46

Dividend	1.69
Forward Dividend	0
Dividend Yield	839.9%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.